Oxidative stress-mediated LDL modification has a key role in initiation of the atherosclerotic process. Platelets produce reactive oxidant species (ROS) upon stimulation with agonist, but it is uncertain whether they are able to oxidatively modify LDL. Human platelets taken from healthy subjects were incubated with LDL, then stimulated with collagen. Compared with unstimulated platelets, collagen-stimulated platelets induced LDL modification as shown by enhanced conjugated dienes and lysophosphatidylcholine formation, electrophoretic mobility, Apo B-100 degradation, and monocyte LDL uptake. Activated platelets also induced a marked reduction of vitamin E contained in LDL. A significant inhibition of LDL oxidation was observed in platelets treated with arachidonyl trifluomethyl ketone (AACOCF3), an inhibitor of phospolipase A2. The experiments reported above were also conducted in patients with hereditary deficiency of gp91phox, the central core of NADPH oxidase, and in patients with hypercholesterolemia. Platelets from gp91 phox-deficient patients produced a small amount of ROS and weakly modified LDL. Conversely, platelets from hypercholesterolemic patients showed enhanced ROS formation and oxidized LDL more than platelets from healthy subjects. This study provides evidence that platelets modify LDL via NADPH oxidase-mediated oxidative stress, a phenomenon that could be dependent on arachidonic acid activation. This finding suggests a role for platelets in favoring LDL accumulation within atherosclerotic plaque.-Carnevale, R., Pignatelli, P., Lenti, L., Buchetti B., Sanguigni, V., Di Santo, S., Violi, F. LDL are oxidatively modified by platelets via GP91 phox and accumulate in human monocytes. FASEB J. 21, 927-934 (2007) 
Lipid-laden foam cells of atherosclerotic plaque are derived primarily from monocyte/macrophages that have taken up oxidized LDL (oxLDL) via the scavenger receptors (1) . Accordingly, administration of vitamin E, a well-known antioxidant, to patients undergoing carotid atherectomy demonstrated a significant inhibition of LDL uptake by human atherosclerotic plaque (2) . Several cells, including endothelial, macrophage, and smooth muscle cells, are likely to play a role in generating oxLDL, as suggested by in vitro studies showing that, under appropriate conditions, these cells convert native LDL to a modified form that is rapidly degraded by macrophages (3) . Cell-mediated modification of LDL is characterized by lipid peroxidation with extensive breakdown of cholesterol, phospholipids, and apolipoprotein B-100 (Apo B-100) (4) . Among circulating cells, platelets may represent another potential stimulus for oxLDL generation. Resting and stimulated platelets (5, 6) produce reactive oxidant species (ROS), such as superoxide anion (O 2 Ϫ ). This has an important role in stimulating platelet function under some conditions such as anoxia-reoxygenation, and also in favoring platelet recruitment (6 -8) . Further support for the idea of production of ROS by stimulated platelets has been provided by experiments showing that platelets express four subunits of NADPH oxidase (8) , one of the most important cellular producers of O 2 Ϫ (9). The relevant role of this enzymatic pathway in generating ROS by activated platelets has been provided by experiments showing that platelets from patients with X-linked chronic granulomatous disease (X-CGD) due to hereditary deficiency of gp91phox, the central core of NADPH oxidase, had almost complete suppression of O 2 Ϫ (9). X-CGD is a rare (1:200.000 live births) primary immunodeficiency affecting the innate immunological system; X-CGD is characterized by life-threatening bacterial and fungal infections (10) . The disease is caused by mutations in any of the four genes encoding subunits of the O 2 Ϫ generating NADPH oxidase, resulting in defective O 2 Ϫ generation and intracellular killing (11) .
Based on these data showing that platelets represent an alternative source of ROS formation, we speculated that they could help to modify LDL, and in turn determine enhanced LDL uptake by macrophages via an oxidative stress-mediated mechanism. Therefore, the first aim of the study was to assess whether, upon stimulation, platelets elicit human LDL oxidation, and in turn enhance LDL uptake by human macrophages. The second aim was to investigate the mechanism through which platelets oxidize LDL. For this purpose, we studied the oxidation of LDL using platelets taken from patients with gp91phox hereditary deficiency.
Here we report for the first time that platelets modify LDL via gp91phox-mediated O 2 Ϫ generation.
MATERIALS AND METHODS

Phospholipids standards
Lysophosphatidylcholine (LPC), sphyngomielin, phosphatidylcholine (PC), posphatidylserine, posphatidylethanolamine, cholesterol, tiacylglicerides, free fatty acid, BIOMAX MR-1 Film, AACOCF3, BSA, HEPES, and acid acetylsalicylic (ASA) were purchased from Sigma (Milan, Italy Paraformaldehyde and all analytical and HPLC grade reagents were purchased from Merck (Darmstadt, Germany). MACS columns were purchased from Miltenyi Biotech GmbH (Bergisch Gladbach, Germany).
Patients' description
We performed a cross-sectional study comparing LDL oxidation elicited by platelets taken from 10 patients with hypercholesterolemia (males 5, females 5, age 44 years) and 10 sexand age-matched normocholesterolemic subjects (males 5, females 5, age 45 years). Patients and controls were recruited from the same geographic area and followed a typical Mediterranean diet. None of the patients had clinical evidence of cardiovascular disease (as shown by clinical history, physical examination or ECG), diabetes mellitus, or hypertension. Patients with hypercholesterolemia had not taken any lipidlowering agents or antiplatelet drugs in the previous 30 days. LDL cholesterol was 191 Ϯ 13 mg/dl in patients and 110 Ϯ 12 mg/dl in controls.
X-CGD, an inherited disorder characterized by an absence or deficiency of phagocyte-NADPH oxidase activity, was diagnosed in two male patients (33 and 38 years of age) by demonstrating the absence or manifest deficiency of oxidase activity in stimulated neutrophils (12) . Blood samples were taken from each patient with X-CGD on three separate occasions.
LDL modification by activated platelets
Oxidation of LDL was carried out by incubating LDL (50 g protein/ml) at 37°C for 30 min with platelets (5ϫ10 8 /ml) taken from healthy subjects (HS), hypercholesterolemic patients (HC), or X-CGD patients and stimulated with collagen (6 g/ml). Collagen was selected as agonist because it elicits much more production of ROS than other agonists, such as ADP or thrombin (13) . To assess the role of PLA2 and cyclooxygenase upon LDL oxidation, AACOCF3 (14 M) or ASA (100 M), selective inhibitors of PLA2 and cyclooxygenase 1 (COX-1), respectively, were incubated for 10 min at 37°C with LDL-treated platelets before agonist stimulation.
Samples were centrifuged for 3 min at 37°C and the supernatant was treated to measure the conjugated dienes, LPC formation, vitamin E consumption, LDL electrophoretic mobility, degradation of Apo B-100, and uptake of oxLDL (see below).
Conjugated dienes
The standard oxidation assay was performed using a Perkin Elmer Lambda 4B UV/VIS spectrometer (Norwalk, CT, USA).
Measurement of the 234 nm absorption was read at intervals of 2 min for a period of 2 h, as described, and expressed as micromoles of conjugated dienes (14) .
Phospholipid analysis
The lipid extracts by Folch et al. (15) were separated on silica gel 60 plates (Merck) with a solvent system of toluene/diethyl ether/ethanol (105: 30: 3, v/v/v). The zones on silica gel corresponding to phospholipids (PLs) were scraped off, extracted with chloroform/methanol (2:1, v/v), and further developed by high-performance thin layer chromatography (HPTLC) with a solvent system of chloroform/methanol/ acetic acid/water (50:37.5:3.5:
Areas containing individual phospholipids were identified by comigration of standards and were visualized by staining with molybdenum blue reagent (16) . Relative quantification of individual lipid classes was performed using the "NIH IMAGE 1.63" and expressed as g/50 mg protein/ml of LDL.
Vitamin E estimation
Samples (100 l) were supplemented with tocopheryl acetate (internal standard), deproteinized by the addition of ethanol, and extracted with hexane. Phase separation was achieved by centrifugation. The collected upper phase was evaporated and analyzed by HPLC (17) . Vitamin E was expressed as 1 g/50 g protein/ml of LDL.
Agarose gel electrophoresis
Electrophoretic mobility was measured in barbital/sodium barbital, pH 8.0 on 1% agarose gel SPE (Beckman Coulter, Fullerton, CA, USA) (18) and expressed as percentage of mobility compared with native LDL.
SDS-polyacrylamide gradient gel electrophoresis
The protein interface was removed during phospholipid extraction. The protein band was then dissolved in sample buffer containing 3% SDS, 10% glycerol, and 5% 2-mercaptoethanol by incubating in boiling water for 3-5 min. Vertical gel electrophoresis was performed according to the method of Laemmli (19) , using a 3-14% gradient acrylamide gel (20) .
Cholesteryl esters content within human macrophages
Human peripheral blood mononuclear cells (monocytes and lymphocytes) were isolated from whole blood as described (21) . To isolate monocytes, we used MS Columns according to the manufacturer's instructions (MACS ® by Miltenyi Biotech GmbH). Monocytes (2ϫ10 6 ) (97% of purity) were cultured in DMEM containing 20% FCS for 24 h. After 24 h each dish was washed with 2 ml of DMEM without serum to remove nonadherent cells. Adherent cells received 1 ml of DMEM containing 50 g/ml modified LDL (see above)
supplemented with [1- 14 C] oleic acid (0.5 Ci/ml) bound to albumin (2 mg/ml) (22) . Monocyte neutral lipids were extracted as described (15) and separated by HPTLC on silica gel 60 plates, with hexane/diethyl ether/acetic acid (70:30:1 v/v/v) as the developing system. Quantitative analyses of the cholesteryl esters were performed by autoradiography using BIOMAX MR-1 film, quantified using "NIH IMAGE 1.63," and by scraping off the area corresponding to cholesteryl oleate and measuring the radioactivity by liquid scintillation counting. For each method, the amount of cholesteryl esters was expressed as nanomoles of cholesteryl [1- 14 C] oleate formed per 50 mg of total cell protein (cholesteryl [1- 14 C] oleate standard was 0.1 mmol).
Statistical analysis
Continuous variables are reported as means Ϯ sd. For each gp91 phox-deficient patient, data reported represent the mean Ϯ sd of three separate experiments. Comparisons between groups were carried out by nonparametric tests (Wilcoxon test for related samples and Mann-Whitney U test for independent samples).
A value of P Ͻ 0.05 was considered statistically significant. All analyses were carried out with Statistical Packages for the Social Sciences 13.0 software (SPSS Inc., Chicago, IL, USA).
RESULTS
Platelet-induced LDL oxidation in patients with hypercholesterolemia
Platelets from HC and HS were studied to see whether they oxidize LDL differently. Three methods were used to explore LDL oxidation, an indirect measure of oxLDL uptake by monocytes: conjugated dienes formation, vitamin E consumption in LDL, and content of cholesteryl esters in monocytes. The study demonstrated a significantly higher rate of LDL oxidation by stimulated platelets taken from HC compared with HS.
The rate of conjugated dienes was 17.32 M Ϯ 1.46 in HC and 14.38 M Ϯ 0.581 in HS (nϭ10, PϽ0.005) (Fig. 1) . Vitamin E consumption was 0.271 g Ϯ 0.057 in HC and 0.400 g Ϯ 0.08 in HS (nϭ10, Pϭ0.001) (Fig. 2) . The content of cholesteryl esters in monocytes was 287 nmol Ϯ 18.5 in HC and 234 nmol Ϯ 28.49 in HS (nϭ10, Pϭ0.038) (Fig. 3) .
In vitro analysis of platelet-induced LDL oxidation
Experiments were conducted by measuring LDL oxidation induced by platelets taken from HS or X-CGD patients. Several assays were used to measure LDL oxidation: formation of conjugated dienes, consumption of vitamin E in LDL, content of cholesteryl esters in monocytes, formation of LPC, LDL electrophoretic mobility, and Apo B-100 degradation.
Conjugated dienes
As shown in Fig. 1 , we compared the rate of conjugated dienes produced by LDL treated with collagen-stimulated platelets from HS vs. LDL treated with unstimulated platelets. The results showed a maximum increase of conjugated dienes production at 30 min in LDL treated with collagen-stimulated platelets compared to LDL treated with unstimulated platelets (14.38 MϮ0.581 vs. 6.27 MϮ1.09, respectively, nϭ10, PϽ0.005). Incubation of LDL with collagen-stimulated platelets supplemented with AACOCF3, an inhibitor of phospholipase A2 (PLA2), resulted in a significant reduction of conjugated dienes compared to LDL treated with collagen-stimulated platelets (7.59 MϮ0.681 vs. 14.38 MϮ0.581, respectively, nϭ10, PϽ0.005); treatment with ASA resulted in a partial but significant reduction of conjugated dienes compared to LDL treated with collagen-stimulated platelets (12.1 MϮ0.438 vs. 14.38 MϮ0.581, respectively, nϭ10, Pϭ0.0013) (Fig. 1) .
Conjugated dienes were also measured in platelets from patients with X-CGD. LDL treated with collagenstimulated platelets showed a marked reduction of conjugated dienes compared to LDL treated with collagen-stimulated platelets from HS (8.45 MϮ1.43 vs. 14.38 MϮ0.581, respectively, nϭ6, PϽ0.0001) (Fig. 1) .
Loss of vitamin E in LDL
Analysis of vitamin E in LDL treated with unstimulated platelets from HS showed a weak but significant decrease of vitamin E compared with native LDL (0.74 gϮ0.10 vs. 0.95 gϮ0.13, respectively, nϭ10, PϽ0.005) (Fig. 2) ; a more marked decrease of vitamin E was observed in LDL treated with collagen-stimulated platelets vs. LDL incubated with unstimulated platelets (0.4 gϮ0.08 vs. 0.74 gϮ0.10, respectively, nϭ10, PϽ0.005) (Fig. 2) . Preincubation of platelets with the inhibitor of PLA2 prevented vitamin E loss compared to LDL treated with collagen-stimulated platelets alone (0.70 g/mgϮ0.05 vs. 0.40 gϮ0.08, respectively, nϭ10, PϽ0.005) (Fig. 2) ; preincubation with ASA par- Experiments were performed in LDL treated with collagenstimulated platelets with or without AACOCF3 and ASA. Platelets were taken from healthy subjects (HS, nϭ10), from hypercholesterolemic patients (HC, nϭ10) , and from Xlinked chronic granulomatous disease patients (X-CGD, nϭ6, 3 determinations for each patient). *P Ͻ 0.005; **P ϭ 0.0013; ***P Ͻ 0.0001. tially prevented vitamin E loss compared to LDL treated with collagen-stimulated platelets alone (0.46 g/mgϮ0.017 vs. 0.40 gϮ0.08, respectively, nϭ10, Pϭ0.04) (Fig. 2) . No change in vitamin E content was observed in LDL treated with collagen-stimulated platelets from X-CGD compared with native LDL (0.84 gϮ0.04 vs. 0.95 gϮ0.13, respectively, nϭ6, Pϭ0.06) (Fig. 2) .
Accumulation of cholesteryl esters in monocytes
Monocytes accumulate large amounts of cholesteryl ester when incubated with human LDL that has been modified by oxidation. This accumulation is related to a high-affinity cell surface binding site that mediates the uptake of oxLDL (23) .
Monocyte incubation with LDL and collagen-stimulated platelets caused a 2-fold increase in the concentration of cholesteryl 14 C oleate compared to LDL incubated with unstimulated platelets (234 nmolϮ28.49 vs. 110 nmolϮ13.62, nϭ10, PϽ0.005) (Fig. 3) . Such an increase in etherified cholesterol was significantly inhibited in the presence of the inhibitor of PLA2 (130 nmolϮ16.2 vs. 234 nmolϮ28.49, nϭ10, PϽ0.005); a partial but significant inhibition was observed with ASA (186.6 nmolϮ18.2 vs. 234 nmolϮ28.49, nϭ10, Pϭ0.001) (Fig. 3) . Conversely, a weak accumulation of cholesteryl 14 C oleate was observed in monocytes incubated with LDL treated with collagen-stimulated platelets from X-CGD patients compared to monocytes incubated with LDL and collagen-stimulated platelets from HS (150.6 nmolϮ16.28 vs. 234 nmolϮ28.49, respectively, nϭ6, PϽ0.0001) (Fig. 3) .
Identification of lysophosphatidylcholine
No difference in LPC content was observed between native LDL and LDL treated with unstimulated platelets from HS (0.277 gϮ0.036 vs. 0.281 gϮ0.034, respectively, nϭ10, Pϭ0.8) (Fig. 4) . An enhanced formation of LPC was detected in LDL treated with collagen-stimulated platelets from HS compared to LDL treated with unstimulated platelets (5.23 gϮ0.82 vs. 0.281 gϮ0.034, respectively, nϭ10, PϽ0.005) (Fig.  4) . In samples to which the inhibitor of PLA2 was added, LPC formation was reduced compared to LDL treated with collagen-stimulated platelets alone (1.45 gϮ0.36 of LDL vs. 5.23Ϯ0.82 g, respectively, nϭ10, PϽ0.005); a less marked reduction was obtained by treating samples with ASA (3.12 gϮ0.42 of LDL vs. 5.23Ϯ0.82 g, respectively, nϭ10, Pϭ0.001) (Fig. 4) . Conversely, LPC was not detected in LDL treated with collagen-stimulated platelets from X-CGD patients compared to LDL treated with collagen-stimulated platelets from HS (0.33 gϮ0.05 vs. 5.23Ϯ0.82 g, respectively, nϭ6, PϽ0.0001) (Fig. 4) .
LDL electrophoresis
We observed a greater mobility in LDL treated with collagen-stimulated platelets from HS compared to LDL treated with unstimulated platelets from HS (64.84Ϯ3.16 vs. 21.68Ϯ2.81, PϽ0.001) (Fig. 5 ). This agrees with other reports (16, 17) showing that oxidation renders the LDL more negatively charged and increases anodic electrophoretic mobility on agarose gel. Preincubation of collagen-stimulated platelets with the inhibitor of PLA2 mitigated electrophoresis mobility of LDL (28 (Fig. 5) .
Conversely, LDL treated with collagen-stimulated platelets from X-CGD patients did not show changes of electrophoretic mobility (4.28Ϯ1.15) (Fig. 5) .
SDS-polyacrylamide gradient gel electrophoresis
The ApoB-100 becomes progressively altered during oxidation; its loss of reactive amino groups and frag- Figure 2 . Vitamin E content in LDL. Experiments were performed in LDL treated with collagen-stimulated platelets with or without AACOCF3 and ASA. Platelets were taken from healthy subjects (HS, nϭ10) , from hypercholesterolemic patients (HC, nϭ10), and from X-CGD patients (nϭ6, three determinations for each patient). *P ϭ 0.001; **P Ͻ 0.005; ***P ϭ 0.04; ****P ϭ 0.006. and ASA. Platelets were taken from healthy subjects (HS, nϭ10), hypercholesterolemic patients (HC, nϭ10), and X-CGD patients (nϭ6, three determinations for each patient). *P ϭ 0.038; **P Ͻ 0.005; ***P ϭ 0.001; ****P Ͻ 0.0001. mentation to smaller peptides can be used as an index of oxidative modification (19) . A partial degradation of ApoB-100 was detected in LDL treated with unstimulated platelets from HS (Fig. 6) . Conversely, in LDL treated with collagen-stimulated platelets, fragmentation of ApoB-100 was observed (Fig. 6) . With the loss of ApoB-100, the appearance of a variety of Coomassie blue-stained bands of lower molecular weight was evident. ApoB-100 electrophoresis was also investigated in LDL treated with collagen-stimulated platelets along with an inhibitor of PLA2. These experiments demonstrated a less marked degradation of ApoB-100 compared to LDL treated with collagen-stimulated platelets alone (Fig. 6) . Apo-B 100 degradation was only partially prevented by LDL treated with collagen-stimulated platelets to which ASA was added (Fig. 6) .
The electrophoresis of ApoB-100 was repeated using platelets from patients with X-CGD and showed only a partial fragmentation of ApoB-100 (Fig. 6) .
DISCUSSION
The present study provides evidence that, upon activation, platelets modify LDL via an oxidative stressmediated mechanism. Thus, native LDL incubated with collagen-stimulated platelets had increased lipid peroxide content compared to unstimulated platelets. Further support for the conversion of native LDL to oxLDL was provided by measuring vitamin E contained in LDL, which is an indirect marker of LDL oxidation because it is sharply consumed concomitantly with the formation of oxLDL (24) . Thus, the vitamin E content of LDL coincubated with collagen-activated platelet was significantly lower than that found in LDL incubated with unstimulated platelets. Finally, LDL electrophoresis showed that platelet stimulation by collagen increased LDL mobility and determined degradation of ApoB-100, suggesting that LDL incubated with activated platelets underwent oxidation of protein moiety.
An earlier study (25) proved that in other cell lines, such as smooth muscle cells, O 2 Ϫ was able to give formation of oxLDL. Thus, incubation of LDL with smooth muscle cells resulted in LDL modification as demonstrated by an increase in thiobarbituric acidreactive substances (TBARS) assay content and electrophoretic mobility. Modification of LDL was prevented by superoxide dismutase, suggesting that O 2 Ϫ production by smooth muscle cells had a key role in LDL modification.
As previous studies have shown that, upon stimulation, platelets produce O 2 Ϫ and that NADPH oxidase activation has a crucial role in agonist-induced platelet O 2 Ϫ generation (8, 9), we investigated whether O 2 Ϫ generated by platelets had a role in the formation of oxLDL. For this purpose, we measured the oxidation of LDL using platelets taken from patients with gp91 phox hereditary deficiency, a human knockout model characterized by almost complete suppression of platelet O 2 Ϫ production (9). The novel finding of our study was that, as opposed to normal platelets, those from patients with gp91 phox deficiency weakly modified LDL. Therefore, compared to experiments performed with normal platelets, formation of conjugated dienes was markedly reduced, LDL mobility was unaffected, and Apo B-100 underwent only partial degradation. This result suggests that O 2 Ϫ platelet production is crucial for LDL modification. Consistent with this finding was the result concerning the content of vitamin E. Thus, whereas the level of vitamin E dropped in LDL to which collagen-stimulated platelets from HS were added, no change in vitamin E was detected in experiments performed with platelets from patients with gp91 phox hereditary deficiency.
Taken together, these data demonstrated that upon stimulation with collagen, platelets are able to oxidize LDL via an NADPH-oxidase dependent mechanism, and suggested that the NADPH oxidase subunit gp91phox has a crucial role in LDL modification.
Further studies were performed to analyze the intracellular signaling through which agonist-induced platelet activation enhanced the formation of ROS. We previously demonstrated that, as for other cell lines (13) , platelet O 2 Ϫ formation is mediated by arachidonic acid-induced NADPH oxidase activation (26) . This also seems to occur in our experimental model, where platelets supplemented with an inhibitor of PLA2 induced less oxidation of LDL, suggesting a role for arachidonic acid pathway in stimulating NADPH oxidase and, in turn, eliciting LDL oxidation. This phenomenon would be only partially attributable to a COX-1 pathway, as ASA less markedly inhibited platelet-induced LDL oxidation than the PLA2 inhibitor. These data suggest that a COX-1-independent pathway is primarily responsible for platelet-induced LDL oxidation.
To the best of our knowledge, there is only one report showing that stimulated platelets modify LDL and enhance LDL accumulation within macrophages. Fogelman et al. (22) demonstrated that malondialdehyde (MDA) produced by thrombin-stimulated platelets reacted with LDL, forming MDA-LDL; plateletmodified LDL was taken up by monocyte-macrophages, suggesting that platelets contribute to the accumulation of cholesterol within atherosclerotic plaques (27) . Our paper extends these findings because it demonstrated that LDL uptake by monocytes occurred with a mechanism involving platelet O 2 Ϫ formation. This hypothesis was supported by experiments with platelets from X-CGD that elicit much less LDL uptake by monocytes compared with normal platelets.
A previous study showed that upon incubation with endothelial cells, LDL uptake by macrophages was also Figure 5 . Determination of LDL oxidation by electrophoretic mobility. Electrophoretic mobility was analyzed in native LDL, LDL treated with unstimulated or collagen-stimulated platelets with or without AACOCF3 and ASA. Platelets were taken from healthy subjects (HS, nϭ10) or patients with X-CGD (nϭ6, three determinations for each patient). *P Ͻ 0.001; **P ϭ 0.001. Figure 6 . Determination of LDL oxidation by apoB 100 degradation. A representative 3-14% SDS-polyacrylamide gel of 16 performed from healthy subjects (HS, nϭ10) and patients with X-linked chronic granulomatous disease (X-CGD, nϭ6). Experiments were performed on native LDL, LDL treated with unstimulated, and collagen-stimulated platelets with or without AACOCF3 and ASA. associated with phospholipids degradation. As much as 40% of the LDL PC was converted to lysophosphatydilcholine by a PLA2-like activity (28) . Inhibition of PLA2 reduced phospholipid as well as LDL degradation, suggesting that phospholipid breakdown has a crucial role in inducing changes leading to LDL modification (28) . In our experimental model, we showed that LDL modification mediated by collagen-stimulated platelets induced extensive hydrolysis of LDL PC to LPC. The role of phospholipid breakdown in generating LDL modification was also evident in our system where incubation of platelets with an inhibitor of PLA2 resulted in inhibition of LDL modification. Additional study is necessary to establish whether phospholipid degradation is dependent on a phospholipase associated with platelets and/or with LDL.
Atherosclerosis is characterized by an inflammatory process that is mediated by resident and nonresident cells of the arterial wall. Among the nonresident cells, the role of platelets as inflammatory cells contributing to the atherosclerotic process has attracted the attention of many researchers. Recently three independent studies focused on activation of platelets as a mechanism implicated in the formation of atherosclerotic lesion (29) . Burger et al. (30) demonstrated that in Apo E-deficient animals platelets contribute to atherosclerotic lesion via up-regulation of P-selectin. Massberg et al. (31) showed that the early stage of atherosclerotic lesion is characterized by platelet adhesion to the endothelium: in particular, prolonged blockage of platelet adhesion by antibodies against GP1b alpha resulted in a decrease of atherosclerotic lesion. Finally, Huo et al. (32) demonstrated that repeated infusions of activated platelets induced atherosclerosis in Apo E-deficient animals with a mechanism involving platelet expression of P-selectin. These data indicate that, once recruited into atherosclerotic lesion, platelets generate a variety of inflammatory molecules that contribute to lesion progression.
The present study provides further insight into the inflammatory property of platelets, as it shows that they modify LDL via a free radical-mediated mechanism and enhance LDL uptake by human macrophages. This effect could be particularly relevant in the early stage of atherosclerosis, where platelets, upon adhesion to the endothelium, could release oxygen free radicals, help to oxidize LDL present in the subintima layer, and eventually promote LDL accumulation within atherosclerotic plaque. Oxidative modification of LDL and LDL uptake by macrophages were more marked with platelets taken from hypercholesterolemic patients compared with platelets from healthy subjects. These preliminary data would indicate that in patients at risk of atherosclerotic disease, platelets could contribute to atherosclerotic progression by an oxidative stress mechanism.
This study has some limitations. Even if platelet expression of gp91phox was a prerequisite for the formation of oxLDL, we cannot exclude the possibility that other free radical-generating pathways may contribute to LDL modification. Furthermore, the intrinsic mechanism through which arachidonic acid activates platelet NADPH oxidase was not investigated. Studies are necessary to explore the other intracellular pathways involved in the activation of such enzymes.
In conclusion, we provide evidence that platelets modify LDL via an oxidative stress-mediated mechanism involving gp91phox activation, and we suggest that this may represent a novel pathway through which platelets contribute to the progression of atherosclerotic disease.
